| |
Audit
|
Compensation
|
Nominating
|
 Jay Kouba, Ph.D.  
|
|
|
|
 Chairman
Jay Kouba, Ph.D., has served as Chairman of the Board since April 2007, and Director since June 2006. From May 2007 until February 2008 he also served as President and Chief Executive Officer of the Company. Since May 2008, Jay Kouba has been the President and Chief Executive Officer of Tetra Vitae Bioscience. Prior to joining Metabolix Dr. Kouba served as the President of Oniro Consulting, a strategic management consulting firm. From January 1999 to December 2005, Dr. Kouba held several positions with BP's Petrochemicals Segment. From August 2004 to December 2005, Dr. Kouba served as senior vice president, strategy, marketing and technology for Innovene BP's olefins and polymers subsidiary, and earlier in 2004, as Vice President, Sales, Marketing and Logistics. Between 1999 and 2003, Dr. Kouba was Vice President, Technology. Dr. Kouba is also a Director of Telles, LLC, Metabolix' joint venture with Archer Daniels Midland Company. Dr. Kouba received a B.S. in Chemistry from Stanford University, a Ph.D. in Chemistry from Harvard University and a M.B.A. from University of Chicago.
|
|
Richard Eno
|
|
|
|
 President and CEO, Director
Richard P. Eno has served as President, Chief Executive Officer and Director since March 2008. Mr. Eno has more than twenty five years of professional experience in the chemicals and energy business. Prior to joining Metabolix, Mr. Eno served as Vice President, Leader Global Oil & Gas Sector at CRA International, a leading provider of management consulting services and economic and financial expertise to global companies. Earlier in his career, he held various roles at Arthur D. Little and Chevron Corporation. Mr. Eno is also a Director of Telles, LLC, Metabolix' joint venture with Archer Daniels Midland Company.Mr. Eno holds a Bachelor of Science Degree in Chemical Engineering from Cornell University, a Masters in Business Administration from the University of Houston and is a Chartered Financial Analyst.
|
|
Dr. Oliver P. Peoples
|
|
|
|
 Chief Scientific Officer, Vice President R&D, Director
Dr. Peoples, a co-founder of Metabolix, has served as our Chief Scientific Officer and
Vice President of Research and Development since January 2000 and was previously our Director of
Research and Vice President. Dr. Peoples has served as a Director since June 1992. Before founding
Metabolix, Dr. Peoples was a research scientist with the Department of Biology at the MIT where he
emerged as a pioneer of the new field of metabolic pathway engineering and its applications in
industrial biotechnology. The research carried out by Dr. Peoples at MIT established the fundamental
tools and methods for engineering bacteria and plants to produce polyhydroxyalkanoates. Dr. Peoples
has published numerous peer-reviewed academic papers and is an inventor of over 90 patents and
patent applications worldwide. Dr. Peoples received a Ph.D. in Molecular Biology from the University
of Aberdeen, Scotland.
|
|
Peter Kellogg
|
|
|
|
 Director
Peter N. Kellogg has served as a Director of the Company since March 2007. Since August 2007, he
has been Executive Vice President and Chief Financial Officer of Merck & Co., Inc. He joined Merck
in 2007 after serving as Executive Vice President, Finance and Chief Financial Officer of Biogen
Idec Inc. From 2000 to 2003, Mr. Kellogg held the same position at Biogen, Inc., which merged with
IDEC Pharmaceuticals in 2003. Before that, he served as Senior Vice President, PepsiCo E-Commerce
at PepsiCo Inc. from March to July 2000 and as Senior Vice President and Chief Financial Officer,
Frito-Lay International, from March 1998 to March 2000. From 1987 to 1998, he served in a variety of
senior financial, international and general management positions at PepsiCo and the Pepsi-Cola
International, Pepsi-Cola North America, and Frito-Lay International divisions. Prior to joining
PepsiCo, Mr. Kellogg was a senior consultant with Arthur Andersen & Co. and Booz Allen &
Hamilton. Mr. Kellogg holds an M.B.A. in Management from the University of Pennsylvania and a B.S.
in Engineering from Princeton University.
|
|
Stephen J. Large
|
|
|
|
 Director
Since 2008, Stephen J. Large has held the position of President and Chief Executive Officer of SI Group, Inc., a multinational producer of chemical intermediates headquartered in Schenectady, NY, USA. During the previous 15 years, Mr. Large held various executive positions with H.B. Fuller, a producer and marketer of adhesives, sealants and coatings. He has lived in the UK, South Africa, New Zealand and the USA and conducted business in most industrial countries in the world. Mr. Large was born and educated in the United Kingdom and holds a B.Sc. in Polymer Science and Technology from the Plastics and Rubber Institute at Manchester Polytechnic.
|
|
Celeste Beeks Mastin
|
|
|
|
 Director
Celeste Beeks Mastin recently served as chief executive officer of MMI Products, Inc., where she had profit/loss responsibility for a $750 million building materials company with 18 manufacturing locations and 2,500 employees. Prior to MMI Products, she spent 17 years in the chemical industry. She served in a variety of positions at Ferro Corporation, including vice president of Color and Glass Performance Materials with profit/loss responsibility for a $400 million global business and as vice president, growth and development. Prior to that, Ms. Mastin served as a vice president and general manager at Bostik, heading the company's $160 million non-wovens division. Ms. Mastin began her career at Shell Chemical Co. where she served for five years in sales positions of increasing responsibility. She holds an M.B.A. from the University of Houston and a B.S. in chemical engineering from Washington State University.
|
|
Professor Anthony J. Sinskey, Sc.D.
|
|
|
|
 Director
Anthony J. Sinskey, Sc.D., a co-founder of Metabolix, has served as a director since June 1992. From 1968 to present, Dr. Sinskey has been on the faculty of the Massachusetts Institute of Technology. Currently at M.I.T., he is Professor of Microbiology in the Department of Biology and Professor of Health Sciences and Technology in the Harvard-M.I.T. Health Sciences and Technology Program, as well as Co-Director of the Center for Biomedical Innovation. Dr. Sinskey serves on the board of directors of Tepha, Inc. Dr. Sinskey received a Sc.D. from Massachusetts Institute of Technology and a B.S. from the University of Illinois.
|
|
Matthew Strobeck
|
|
|
|
From June 2008 to October 2011, Dr. Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management, an investment firm with approximately $15 billion in assets under management. Dr. Strobeck organized and completed the repurchase of Westfield in 2008 from Boston Private Bank, and prior to this transaction he was a member of the investment team. Dr. Strobeck received a B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, an S.M. from the Harvard University-MIT Health Sciences Technology Program and an S.M. from the MIT Sloan School of Management.
|
|
Robert L. Van Nostrand
|
|
|
|
 Director
Robert L. Van Nostrand has served as a director since October 2006. He was the Executive Vice President and Chief Financial Officer of AGI Dermatics, a bio-pharmaceutical laboratory specializing in skin photobiology until October 2008 when the company was sold. Previously, Mr. Van Nostrand was with OSI Pharmaceuticals, Inc. for 21 years, most recently as the Senior Vice President and Chief Compliance Officer from 2005 until August 2007, and as the Vice President and Chief Financial Officer from 1996 through 2005. Prior to joining OSI, Mr. Van Nostrand was in a managerial position with Touche Ross & Co. (currently Deloitte and Touche). Mr. Van Nostrand serves on the board of directors of Apex Bioventures, Inc., a special purpose acquisition company focused in life sciences, and is Chairman of its audit committee, and he is on the board of Achillion Pharmaceuticals, Inc, a biotechnology company focused on infectious disease, and is Chairman of its audit committee. Mr. Van Nostrand received a B.S. in Accounting from Long Island University, New York, and completed advanced management studies at the Wharton School. Mr. Van Nostrand is a Certified Public Accountant.
|
|
Barbara Wells
|
|
|
|
 Director
Barbara H. Wells, Ph.D., is currently the president and chief executive officer of ArborGen, which she joined in 2002. Prior to ArborGen, she was vice president in charge of Latin American growth initiatives and investments for Emergent Genetics, an agricultural investment firm. Dr. Wells also spent 18 years at Monsanto where her roles included serving as co-managing director of Monsanto Brazil and leader of the Roundup Ready soybean team. Throughout her career, she has developed international commercial and technical experience in agriculture, biotechnology and forestry.
|
You can contact Metabolix, Inc.'s Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Metabolix, Inc. board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
You may also communicate online with our Board of Directors as a group.
Delicious
Digg
Facebook
LinkedIn
Twitter